•  

Vasomune Therapeutics Inc.

Dr. Raphael Hofstein in Biotechnology Focus: Canada’s Contagiously Creative Life Sciences Sector

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published the following guest column by Dr. Raphael Hofstein, MaRS Innovation’s president & CEO, and Elizabeth Monier-Williams, director of marketing and communications. There’s a historical trend in Canadian culture with far-reaching effects for the way we do business, ranging from entertainment to academia to science. Namely, it’s that until quite recently, Canadians weren’t into cultivating national star systems. [1] As Gideon Hayden recently wrote for TechCrunch, if you’re a Canadian tall poppy ...
June 7, 2016 in Encycle Therapeutics, Government Partners, Industry Partners, Media Coverage, News, Partnerships, Sunnybrook Health Sciences Centre, Triphase Accelerator Corporation, University of Toronto, Vasomune Therapeutics Inc.
Read more

MaRS Innovation’s top 10 portfolio stories for 2014

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses. Here are our picks for the top 10 news stories from MaRS Innovation's portfolio. 1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ...
December 15, 2014 in Acquisitions, BlueDot, CoursePeer, Crowdmark, Encycle Therapeutics, eQOL Inc., Flybits, Funding or Fundraising-Announcements, Government Partners, Granata Decision Systems, Industry Partners, Licenseable Technologies, Media Coverage, Member Institutions, News, OtoSim Inc., Partnerships, Portfolio, Ryerson University, St. Michael's Hospital, Start-Up Companies, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), Thunder Bay Regional Research Institute (TBRRI), TrendMD, Triphase Accelerator Corporation, University Health Network, University of Toronto, UTEST Program, Vasomune Therapeutics Inc., Whirlscape, XLV Diagnostics Inc., York University
Read more

BioCentury features Vasomune Therapeutics

Vasomune Therapeutics, a MaRS Innovation start-up company from Sunnybrook Health Sciences Centre's Sunnybrook Research Institute, was featured in a BioCentury emerging company profile by Michael J. Haas. The company is currently raising a Series A financing round and recently closed a seed investment with Genome Canada and an unnamed industry partner. MaRS Innovation also contributed a third of the investment, bringing the round's total to $1.5 million. Haas' profile, "Vasomune: Lassoing Tie2," is available behind a paywall on the BioCentury website. Here's a short ...
October 27, 2014 in Media Coverage, Member Institutions, News, Portfolio, Start-Up Companies, Sunnybrook Health Sciences Centre, TIAP Staff, Vasomune Therapeutics Inc.
Read more

Vasomune Therapeutics awarded $1.5 million to advance lead asset for renal disease

TORONTO (October 20, 2014) — Vasomune Therapeutics, a biotechnology start-up founded by Drs. Dan Dumont and Paul Van Slyke of Sunnybrook Research Institute (SRI) in partnership with MaRS Innovation, has received $1.5 million, in part through Genome Canada’s Genomic Applications Partnership Program (GAPP), to advance Vasculotide, the company’s lead Tie-2 activating agent, towards clinical development. This announcement was covered in Biotechnology Focus. The Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, announced ...
October 20, 2014 in Funding or Fundraising-Announcements, Government Partners, Industry Partners, Member Institutions, News, Partnerships, Portfolio, Start-Up Companies, Sunnybrook Health Sciences Centre, Vasomune Therapeutics Inc.
Read more